{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:06:12Z","timestamp":1780484772922,"version":"3.54.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100022015","name":"Fakultas Teknik Universitas Indonesia","doi-asserted-by":"publisher","award":["PKS-3702\/UN2.F4.D\/PPM.00.00\/2025"],"award-info":[{"award-number":["PKS-3702\/UN2.F4.D\/PPM.00.00\/2025"]}],"id":[{"id":"10.13039\/501100022015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02016-0","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:48:39Z","timestamp":1772016519000},"page":"1789-1807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential of CAR-Macrophages Derived from Induced Pluripotent Stem Cells (iMacs) for Solid Tumor Therapy"],"prefix":"10.1007","volume":"84","author":[{"given":"Sabrina Lazimmatus","family":"Sofa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libbyfayza Aiko Nabilla","family":"Jamaludin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shofiyah","family":"Shofiyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Parahita","family":"Zubaidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunga Fadhilah","family":"Sunaryo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangga Dwi","family":"Andhika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara Nur","family":"Amalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizal","family":"Azis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2016_CR1","doi-asserted-by":"publisher","unstructured":"Chen, S., Saeed, A. F. U. H., Liu, Q. (2023). Macrophages in immunoregulation and therapeutics. Signal Transduction and Targeted Therapy 2023 8:1 8:1\u201335. https:\/\/doi.org\/10.1038\/s41392-023-01452-1","DOI":"10.1038\/s41392-023-01452-1"},{"key":"2016_CR2","doi-asserted-by":"publisher","unstructured":"Lyadova, I., & Vasiliev, A. (2022). Macrophages derived from pluripotent stem cells: prospective applications and research gaps. Cell & Bioscience 2022 12:1 12:1\u201325. https:\/\/doi.org\/10.1186\/S13578-022-00824-4","DOI":"10.1186\/S13578-022-00824-4"},{"key":"2016_CR3","doi-asserted-by":"publisher","unstructured":"Rashid, R., Banday, S., Sharma, A., & Mishra, A. K. (2025). CAR-Ms: Macrophage-Based cellular immunotherapies for solid tumors. Cell-based Immunotherapies for Cancer, 377\u2013391. https:\/\/doi.org\/10.1007\/978-3-031-88695-9_15","DOI":"10.1007\/978-3-031-88695-9_15"},{"key":"2016_CR4","doi-asserted-by":"publisher","first-page":"1615760","DOI":"10.3389\/FIMMU.2025.1615760\/FULL","volume":"16","author":"A Morva","year":"2025","unstructured":"Morva, A., Arroyo, A. B., Andreeva, L., et al. (2025). Unleashing the power of CAR-M therapy in solid tumors: A comprehensive review. Frontiers in Immunology, 16, 1615760. https:\/\/doi.org\/10.3389\/FIMMU.2025.1615760\/FULL","journal-title":"Frontiers in Immunology"},{"key":"2016_CR5","doi-asserted-by":"publisher","unstructured":"Zhu, S., Yi, M., Wu, Y. (2021). Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Experimental Hematology & Oncology 2021 10:1 10:1\u201317. https:\/\/doi.org\/10.1186\/S40164-021-00252-Z","DOI":"10.1186\/S40164-021-00252-Z"},{"key":"2016_CR6","doi-asserted-by":"publisher","first-page":"103320","DOI":"10.1016\/J.XPRO.2024.103320","volume":"5","author":"AK Mishra","year":"2024","unstructured":"Mishra, A. K., Banday, S., Thakare, R. P., et al. (2024). Protocol for monitoring phagocytosis of cancer cells by TAM-like macrophages using imaging cytometry. STAR Protoc, 5, 103320. https:\/\/doi.org\/10.1016\/J.XPRO.2024.103320","journal-title":"STAR Protoc"},{"key":"2016_CR7","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.3390\/IJMS21134808","volume":"21","author":"S Gutbier","year":"2020","unstructured":"Gutbier, S., Wanke, F., Dahm, N., et al. (2020). Large-Scale production of human iPSC-Derived macrophages for drug screening. International Journal of Molecular Sciences 2020, 21, 4808. https:\/\/doi.org\/10.3390\/IJMS21134808","journal-title":"International Journal of Molecular Sciences 2020"},{"key":"2016_CR8","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1097\/JS9.0000000000001892","volume":"110","author":"P Mohite","year":"2024","unstructured":"Mohite, P., Puri, A., Dave, R., et al. (2024). Unlocking the therapeutic potential: Odyssey of induced pluripotent stem cells in precision cell therapies. International Journal of Surgery, 110, 6432\u20136455. https:\/\/doi.org\/10.1097\/JS9.0000000000001892","journal-title":"International Journal of Surgery"},{"key":"2016_CR9","doi-asserted-by":"publisher","unstructured":"Zhang, L., Tian, L., Dai, X. (2020). Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. Journal of Hematology & Oncology 2020 13:1 13:1\u20135. https:\/\/doi.org\/10.1186\/S13045-020-00983-2","DOI":"10.1186\/S13045-020-00983-2"},{"key":"2016_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah, Z., Tian, L., Li, Z., et al. (2024). Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell, 31, 803\u2013817e6. https:\/\/doi.org\/10.1016\/j.stem.2024.03.018","journal-title":"Cell Stem Cell"},{"issue":"1 16","key":"2016_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini, S., Gabbasov, R., Oliveira-Nunes, M. C., et al. (2025). Chimeric antigen receptor macrophages (CAR-M) sensitize HER2\u2009+\u2009solid tumors to PD1 Blockade in pre-clinical models. Nature Communications 2025, 16(1 16), 706. https:\/\/doi.org\/10.1038\/s41467-024-55770-1","journal-title":"Nature Communications 2025"},{"key":"2016_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/EXD.14729","volume":"32","author":"S Fukushima","year":"2023","unstructured":"Fukushima, S., Miyashita, A., Kuriyama, H., et al. (2023). Future prospects for cancer immunotherapy using induced pluripotent stem cell-derived dendritic cells or macrophages. Experimental Dermatology, 32, 290\u2013296. https:\/\/doi.org\/10.1111\/EXD.14729;CTYPE:STRING:JOURNAL.","journal-title":"Experimental Dermatology"},{"key":"2016_CR13","doi-asserted-by":"publisher","first-page":"A1000","DOI":"10.1136\/JITC-2021-SITC2021.951","volume":"9","author":"K Reiss","year":"2021","unstructured":"Reiss, K., Yuan, Y., Barton, D., et al. (2021). 951\u2005A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: Preliminary safety, pharmacokinetics, and TME reprogramming data. Journal for Immunotherapy of Cancer, 9, A1000\u2013A1000. https:\/\/doi.org\/10.1136\/JITC-2021-SITC2021.951","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1 17","key":"2016_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/S13045-024-01635-5","volume":"17","author":"X Li","year":"2024","unstructured":"Li, X., Wang, X., Wang, H., et al. (2024). A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy. Journal of Hematology & Oncology 2024, 17(1 17), 116\u2013. https:\/\/doi.org\/10.1186\/S13045-024-01635-5","journal-title":"Journal of Hematology & Oncology 2024"},{"key":"2016_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000540473","volume":"52","author":"PL Lindenbergh","year":"2025","unstructured":"Lindenbergh, P. L., & Van Der Stegen, S. J. C. (2025). Adoptive cell therapy from the dish: Potentiating induced pluripotent stem cells. Transfusion Medicine and Hemotherapy, 52, 27\u201341. https:\/\/doi.org\/10.1159\/000540473","journal-title":"Transfusion Medicine and Hemotherapy"},{"key":"2016_CR16","doi-asserted-by":"publisher","unstructured":"Chou, B. K., Mali, P., Huang, X. (2011). Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Research 2011 21:3 21:518\u2013529. https:\/\/doi.org\/10.1038\/cr.2011.12","DOI":"10.1038\/cr.2011.12"},{"key":"2016_CR17","doi-asserted-by":"publisher","unstructured":"Yu, C., Zhang, M., Xiong, Y. (2023). Comparison of miRNA transcriptome of exosomes in three categories of somatic cells with derived iPSCs. Scientific Data 2023 10:1 10:1\u201312. https:\/\/doi.org\/10.1038\/s41597-023-02493-5","DOI":"10.1038\/s41597-023-02493-5"},{"key":"2016_CR18","doi-asserted-by":"publisher","first-page":"640703","DOI":"10.3389\/FCELL.2021.640703\/FULL","volume":"9","author":"I Lyadova","year":"2021","unstructured":"Lyadova, I., Gerasimova, T., & Nenasheva, T. (2021). Macrophages derived from human induced pluripotent stem cells: The diversity of Protocols, future Prospects, and outstanding questions. Front Cell Dev Biol, 9, 640703. https:\/\/doi.org\/10.3389\/FCELL.2021.640703\/FULL","journal-title":"Front Cell Dev Biol"},{"key":"2016_CR19","doi-asserted-by":"publisher","first-page":"16087","DOI":"10.3390\/IJMS232416087\/S1","volume":"23","author":"A Klepikova","year":"2022","unstructured":"Klepikova, A., Nenasheva, T., Sheveleva, O., et al. (2022). iPSC-Derived macrophages: The differentiation protocol affects cell immune characteristics and differentiation trajectories. International Journal of Molecular Sciences, 23, 16087. https:\/\/doi.org\/10.3390\/IJMS232416087\/S1","journal-title":"International Journal of Molecular Sciences"},{"key":"2016_CR20","doi-asserted-by":"publisher","unstructured":"Bussi, C., Lai, R., Athanasiadi, N., & Gutierrez, M. G. (2024). Physiologic medium renders human iPSC-derived macrophages permissive for M. tuberculosis by rewiring organelle function and metabolism. mBio, 15. https:\/\/doi.org\/10.1128\/MBIO.00353-24;WGROUP:STRING:PUBLICATION.","DOI":"10.1128\/MBIO.00353-24"},{"key":"2016_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/INTIMM\/DXM137","volume":"20","author":"CS Chiang","year":"2008","unstructured":"Chiang, C. S., Chen, F. H., Hong, J. H., et al. (2008). Functional phenotype of macrophages depends on assay procedures. International Immunology, 20, 215\u2013222. https:\/\/doi.org\/10.1093\/INTIMM\/DXM137","journal-title":"International Immunology"},{"key":"2016_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/CIRCRESAHA.117.305860","volume":"117","author":"H Zhang","year":"2015","unstructured":"Zhang, H., Xue, C., Shah, R., et al. (2015). Functional analysis and transcriptomic profiling of iPSC-Derived macrophages and their application in modeling Mendelian disease. Circ Res, 117, 17\u201328. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.305860;WGROUP:STRING:PUBLICATION.","journal-title":"Circ Res"},{"key":"2016_CR23","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/J.REGEN.2022.100061","volume":"17","author":"M Schinke","year":"2022","unstructured":"Schinke, M., Meyer, G., Rafiei Hashtchin, A., et al. (2022). Polarization of human iPSC-derived macrophages directs their immunological response to secondary pro-inflammatory stimuli. J Immunol Regen Med, 17, 100061. https:\/\/doi.org\/10.1016\/J.REGEN.2022.100061","journal-title":"J Immunol Regen Med"},{"key":"2016_CR24","doi-asserted-by":"publisher","unstructured":"Volpato, V., & Webber, C. (2020). Addressing variability in iPSC-derived models of human disease: Guidelines to promote reproducibility. DMM Disease Models and Mechanisms, 13. https:\/\/doi.org\/10.1242\/DMM.042317\/223104","DOI":"10.1242\/DMM.042317\/223104"},{"key":"2016_CR25","doi-asserted-by":"publisher","first-page":"608802","DOI":"10.3389\/FIMMU.2020.608802\/BIBTEX","volume":"11","author":"N Craig-Mueller","year":"2020","unstructured":"Craig-Mueller, N., Hammad, R., Elling, R., et al. (2020). Modeling MyD88 deficiency in vitro provides new insights in its function. Frontiers in Immunology, 11, 608802. https:\/\/doi.org\/10.3389\/FIMMU.2020.608802\/BIBTEX","journal-title":"Frontiers in Immunology"},{"key":"2016_CR26","doi-asserted-by":"publisher","unstructured":"Hai, Q., Bazeley, P., Han, J., et al. (2025). Optimized method to generate Well-Characterized macrophages from induced pluripotent stem cells. Biomedicines, 13. https:\/\/doi.org\/10.3390\/BIOMEDICINES13010099","DOI":"10.3390\/BIOMEDICINES13010099"},{"key":"2016_CR27","doi-asserted-by":"publisher","first-page":"e0250107","DOI":"10.1371\/JOURNAL.PONE.0250107","volume":"16","author":"C Munn","year":"2021","unstructured":"Munn, C., Burton, S., Dickerson, S., et al. (2021). Generation of cryopreserved macrophages from normal and genetically engineered human pluripotent stem cells for disease modelling. PLoS One, 16, e0250107. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0250107","journal-title":"PLoS One"},{"key":"2016_CR28","doi-asserted-by":"publisher","first-page":"e0243807","DOI":"10.1371\/JOURNAL.PONE.0243807","volume":"15","author":"S Monkley","year":"2020","unstructured":"Monkley, S., Krishnaswamy, J. K., G\u00f6ransson, M., et al. (2020). Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterparts. PLoS One, 15, e0243807. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0243807","journal-title":"PLoS One"},{"key":"2016_CR29","doi-asserted-by":"publisher","first-page":"105390","DOI":"10.1016\/j.ebiom.2024.105390","volume":"109","author":"X Zhen","year":"2024","unstructured":"Zhen, X., Kim, J., Kang, J. S., et al. (2024). Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3\u03b6 from human pluripotent stem cells. EBioMedicine, 109, 105390. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105390","journal-title":"EBioMedicine"},{"key":"2016_CR30","doi-asserted-by":"publisher","unstructured":"Paasch, D., Meyer, J., Stamopoulou, A. (2022). Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy. Cells 2022, Vol 11, Page 994 11:994. https:\/\/doi.org\/10.3390\/CELLS11060994","DOI":"10.3390\/CELLS11060994"},{"key":"2016_CR31","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.3390\/IJMS252212223","volume":"25","author":"J Wang","year":"2024","unstructured":"Wang, J., He, Y., Hu, F., et al. (2024). Metabolic reprogramming of immune cells in the tumor microenvironment. International Journal of Molecular Sciences 2024, 25, 12223. https:\/\/doi.org\/10.3390\/IJMS252212223. Page 12223 25:.","journal-title":"International Journal of Molecular Sciences 2024"},{"key":"2016_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang, J., Webster, S., Duffin, B., et al. (2023). Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports, 18, 585\u2013596. https:\/\/doi.org\/10.1016\/j.stemcr.2022.12.012","journal-title":"Stem Cell Reports"},{"key":"2016_CR33","doi-asserted-by":"publisher","first-page":"103721","DOI":"10.1016\/J.SCR.2025.103721","volume":"86","author":"S Wang","year":"2025","unstructured":"Wang, S., Feng, Y., Xing, Q., et al. (2025). Generation of an anti-CD19 CAR knock-in human induced pluripotent stem cell line using CRISPR\/Cas9 technology. Stem Cell Res, 86, 103721. https:\/\/doi.org\/10.1016\/J.SCR.2025.103721","journal-title":"Stem Cell Res"},{"key":"2016_CR34","doi-asserted-by":"publisher","first-page":"2410508","DOI":"10.3390\/IJMS241310508","volume":"24","author":"P Klaihmon","year":"2023","unstructured":"Klaihmon, P., Kang, X., Issaragrisil, S., & Luanpitpong, S. (2023). Generation and functional characterization of Anti-CD19 chimeric antigen Receptor-Natural killer cells from human induced pluripotent stem cells. International Journal of Molecular Sciences 2023, 24, 2410508. https:\/\/doi.org\/10.3390\/IJMS241310508","journal-title":"International Journal of Molecular Sciences 2023"},{"key":"2016_CR35","doi-asserted-by":"publisher","unstructured":"Lei, A., Hua, Y., Lu, S. (2022). A chimera antigen receptor containing TLR4 signaling domain enhances CAR-iMACs polarization and potency against Solid Tumors. https:\/\/doi.org\/10.21203\/RS.3.RS-1279112\/V1","DOI":"10.21203\/RS.3.RS-1279112\/V1"},{"key":"2016_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/J.LFS.2018.06.015","volume":"207","author":"H Zhang","year":"2018","unstructured":"Zhang, H., Li, L., & Liu, L. (2018). Fc\u03b3RI (CD64) contributes to the severity of immune inflammation through regulating NF-\u03baB\/NLRP3 inflammasome pathway. Life Sciences, 207, 296\u2013303. https:\/\/doi.org\/10.1016\/J.LFS.2018.06.015","journal-title":"Life Sciences"},{"key":"2016_CR37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/J.JCONREL.2024.11.064","volume":"377","author":"F Du","year":"2025","unstructured":"Du, F., Ye, Z., He, A., et al. (2025). An engineered \u03b11\u03b21 integrin-mediated Fc\u03b3RI signaling component to control enhanced CAR macrophage activation and phagocytosis. Journal of Controlled Release, 377, 689\u2013703. https:\/\/doi.org\/10.1016\/J.JCONREL.2024.11.064","journal-title":"Journal of Controlled Release"},{"key":"2016_CR38","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/FIMMU.2021.783305\/FULL","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas, C., Gill, S., & Klichinsky, M. (2021). Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. Frontiers in Immunology, 12, 783305. https:\/\/doi.org\/10.3389\/FIMMU.2021.783305\/FULL","journal-title":"Frontiers in Immunology"},{"key":"2016_CR39","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1136\/JITC-2021-002460","volume":"9","author":"E Beyranvand Nejad","year":"2021","unstructured":"Beyranvand Nejad, E., Labrie, C., Van Elsas, M. J., et al. (2021). IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. Journal for Immunotherapy of Cancer, 9, 2460. https:\/\/doi.org\/10.1136\/JITC-2021-002460","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"2016_CR40","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/J.BIOPHA.2024.116930","volume":"177","author":"W Zhang","year":"2024","unstructured":"Zhang, W., Wang, M., Ji, C., et al. (2024). Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomedicine & Pharmacotherapy, 177, 116930. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.116930","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2016_CR41","doi-asserted-by":"publisher","unstructured":"Klichinsky, M., Ruella, M., Shestova, O. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology 2020 38:8 38:947\u2013953. https:\/\/doi.org\/10.1038\/s41587-020-0462-y","DOI":"10.1038\/s41587-020-0462-y"},{"key":"2016_CR42","doi-asserted-by":"publisher","unstructured":"Arima, Y., Matsueda, S., & Saya, H. (2023). Significance of Cancer-Associated Fibroblasts in the Interactions of Cancer Cells with the Tumor Microenvironment of Heterogeneous Tumor Tissue. Cancers 2023, Vol 15, Page 2536 15:2536. https:\/\/doi.org\/10.3390\/CANCERS15092536","DOI":"10.3390\/CANCERS15092536"},{"key":"2016_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/OR.2025.8926\/HTML","volume":"54","author":"X Liu","year":"2025","unstructured":"Liu, X., Wang, C., Mao, H., & Wei, J. (2025). Crosstalk between cancerassociated fibroblasts and inflammation in tumor microenvironment: A novel perspective in cancer therapy (Review). Oncology Reports, 54, 1\u201313. https:\/\/doi.org\/10.3892\/OR.2025.8926\/HTML","journal-title":"Oncology Reports"},{"key":"2016_CR44","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/jid.2014.488","volume":"135","author":"SC Han","year":"2015","unstructured":"Han, S. C., Koo, D. H., Kang, N. J., et al. (2015). Docosahexaenoic acid alleviates atopic dermatitis by generating Tregs and IL-10\/TGF-\u03b2-modified macrophages via a TGF-\u03b2-dependent mechanism. Journal of Investigative Dermatology, 135, 1556\u20131564. https:\/\/doi.org\/10.1038\/jid.2014.488","journal-title":"Journal of Investigative Dermatology"},{"key":"2016_CR45","doi-asserted-by":"publisher","unstructured":"Luo, F., Li, H., Ma, W. (2023). The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cellular & Molecular Immunology 2023 21:1 21:60\u201379. https:\/\/doi.org\/10.1038\/s41423-023-01112-y","DOI":"10.1038\/s41423-023-01112-y"},{"issue":"1 14","key":"2016_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-41470-9","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang, X., Su, S., Zhu, Y., et al. (2023). Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nature Communications 2023, 14(1 14), 1\u201315. https:\/\/doi.org\/10.1038\/s41467-023-41470-9","journal-title":"Nature Communications 2023"},{"issue":"1 16","key":"2016_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-59326-9","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen, S., Wang, Y., Dang, J., et al. (2025). CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. Nature Communications 2025, 16(1 16), 1\u201320. https:\/\/doi.org\/10.1038\/s41467-025-59326-9","journal-title":"Nature Communications 2025"},{"issue":"1 9","key":"2016_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40364-020-00251-Y","volume":"9","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Xu, R., Gu, H., et al. (2021). Metabolic reprogramming in macrophage responses. Biomarker Research 2021, 9(1 9), 1\u201317. https:\/\/doi.org\/10.1186\/S40364-020-00251-Y","journal-title":"Biomarker Research 2021"},{"key":"2016_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stem.2024.05.006","volume":"31","author":"D Paasch","year":"2024","unstructured":"Paasch, D., & Lachmann, N. (2024). CAR macrophages tuning the immune symphony of anti-cancer therapies. Cell Stem Cell, 31, 791\u2013793. https:\/\/doi.org\/10.1016\/j.stem.2024.05.006","journal-title":"Cell Stem Cell"},{"key":"2016_CR50","doi-asserted-by":"publisher","unstructured":"Guan, F., Wang, R., Yi, Z. (2025). Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduction and Targeted Therapy 2025 10:1 10:1\u201367. https:\/\/doi.org\/10.1038\/s41392-025-02124-y","DOI":"10.1038\/s41392-025-02124-y"},{"key":"2016_CR51","doi-asserted-by":"publisher","first-page":"116129","DOI":"10.1016\/j.bone.2021.116129","volume":"153","author":"K Matsuo","year":"2021","unstructured":"Matsuo, K., Lepinski, A., Chavez, R. D., et al. (2021). ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages. Bone, 153, 116129. https:\/\/doi.org\/10.1016\/j.bone.2021.116129","journal-title":"Bone"},{"issue":"3 25","key":"2016_CR52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/S10555-006-9001-7","volume":"25","author":"A Mantovani","year":"2006","unstructured":"Mantovani, A., Schioppa, T., Porta, C., et al. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews 2006, 25(3 25), 315\u2013322. https:\/\/doi.org\/10.1007\/S10555-006-9001-7","journal-title":"Cancer and Metastasis Reviews 2006"},{"key":"2016_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.TRECAN.2015.11.004","volume":"2","author":"RA Franklin","year":"2016","unstructured":"Franklin, R. A., & Li, M. O. (2016). Ontogeny of Tumor-Associated macrophages and its implication in cancer regulation. Trends Cancer, 2, 20\u201334. https:\/\/doi.org\/10.1016\/J.TRECAN.2015.11.004","journal-title":"Trends Cancer"},{"key":"2016_CR54","doi-asserted-by":"publisher","unstructured":"Dieli, F., & Farhan Saeed, A. (2025). Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy. Cells 2025, Vol 14, Page 741 14:741. https:\/\/doi.org\/10.3390\/CELLS14100741","DOI":"10.3390\/CELLS14100741"},{"issue":"4 131","key":"2016_CR55","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko, J. H., & Hollm\u00e9n, M. (2024). Clinical landscape of macrophage-reprogramming cancer immunotherapies. British Journal of Cancer 2024, 131(4 131), 627\u2013640. https:\/\/doi.org\/10.1038\/s41416-024-02715-6","journal-title":"British Journal of Cancer 2024"},{"key":"2016_CR56","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1017\/ERM.2025.10006","volume":"27","author":"P Chen","year":"2025","unstructured":"Chen, P., Gao, J., Feng, J., et al. (2025). The application of iPSCs in tumour immunotherapy. Expert Reviews in Molecular Medicine, 27, e26. https:\/\/doi.org\/10.1017\/ERM.2025.10006","journal-title":"Expert Reviews in Molecular Medicine"},{"key":"2016_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-025-01170-7","volume":"9","author":"M Alrehaili","year":"2025","unstructured":"Alrehaili, M., Couto, P. S., Khalife, R., & Rafiq, Q. A. (2025). CAR-macrophages in solid tumors: promise, progress, and prospects. Npj Precision Oncology 2025, 9, 1. https:\/\/doi.org\/10.1038\/s41698-025-01170-7","journal-title":"Npj Precision Oncology 2025"},{"key":"2016_CR58","doi-asserted-by":"publisher","first-page":"A1740","DOI":"10.1136\/JITC-2023-SITC2023.1515","volume":"11","author":"K Haake","year":"2023","unstructured":"Haake, K., Mirenda, M., Bernard, Q., et al. (2023). 1515\u2005Gene edited iPSC-derived macrophages (iMACs) show increased phagocytosis in pre-clinical tumor models. Journal for Immunotherapy of Cancer, 11, A1740\u2013A1740. https:\/\/doi.org\/10.1136\/JITC-2023-SITC2023.1515","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"2016_CR59","doi-asserted-by":"publisher","first-page":"105301","DOI":"10.1016\/j.ebiom.2024.105301","volume":"107","author":"J Liu","year":"2024","unstructured":"Liu, J., Bai, Y., Li, Y., et al. (2024). Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: An immunometabolism perspective. EBioMedicine, 107, 105301. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105301","journal-title":"EBioMedicine"},{"key":"2016_CR60","doi-asserted-by":"publisher","unstructured":"Su, S., Lei, A., Wang, X. (2022). Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies. Cells 2022, Vol 11, Page 1652 11:1652. https:\/\/doi.org\/10.3390\/CELLS11101652","DOI":"10.3390\/CELLS11101652"},{"key":"2016_CR61","doi-asserted-by":"publisher","first-page":"A355","DOI":"10.1136\/JITC-2022-SITC2022.0337","volume":"10","author":"K Haake","year":"2022","unstructured":"Haake, K., Mirenda, M., Bousquet, J., et al. (2022). 337\u2005Development of potent iPSC-derived macrophages (iMACs) for off-the-shelf cancer immunotherapy \u2013 a new cell type in the EVOcells platform. Journal for Immunotherapy of Cancer, 10, A355\u2013A355. https:\/\/doi.org\/10.1136\/JITC-2022-SITC2022.0337","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"2016_CR62","doi-asserted-by":"publisher","first-page":"1723270","DOI":"10.3389\/FIMMU.2025.1723270","volume":"16","author":"Y-M Yang","year":"2026","unstructured":"Yang, Y-M., Ding, Y-F., Hu, Y-Y., et al. (2026). CAR-M therapy in the era of tumor immunotherapy: Current research progress and engineering strategies. Frontiers in Immunology, 16, 1723270. https:\/\/doi.org\/10.3389\/FIMMU.2025.1723270","journal-title":"Frontiers in Immunology"},{"key":"2016_CR63","doi-asserted-by":"publisher","unstructured":"Senju, S., Koba, C., Haruta, M. (2014). Application of iPS cell-derived macrophages to cancer therapy. Oncoimmunology 3:. https:\/\/doi.org\/10.4161\/ONCI.27927;REQUESTEDJOURNAL:JOURNAL:KONI20;ISSUE:ISSUE:DOI.","DOI":"10.4161\/ONCI.27927"},{"key":"2016_CR64","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1038\/s41586-023-06950-4","volume":"626","author":"Z Deng","year":"2024","unstructured":"Deng, Z., Loyher, P. L., Lazarov, T., et al. (2024). The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature 2024, 626, 8000. https:\/\/doi.org\/10.1038\/s41586-023-06950-4","journal-title":"Nature 2024"},{"key":"2016_CR65","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMOA1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E., Marin, D., Banerjee, P., et al. (2020). Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. New England Journal of Medicine, 382, 545\u2013553. https:\/\/doi.org\/10.1056\/NEJMOA1910607;ISSUE:ISSUE:DOI.","journal-title":"New England Journal of Medicine"},{"key":"2016_CR66","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin, R., Graham, C., Yallop, D., et al. (2020). Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies. The Lancet, 396, 1885\u20131894. https:\/\/doi.org\/10.1016\/S0140-6736(20)32334-5","journal-title":"The Lancet"},{"key":"2016_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/IJMS21010089","volume":"21","author":"PR Pandey","year":"2019","unstructured":"Pandey, P. R., Tomney, A., Woon, M. T., et al. (2019). End-to-End platform for human pluripotent stem cell manufacturing. International Journal of Molecular Sciences 2020, 21, 89. https:\/\/doi.org\/10.3390\/IJMS21010089","journal-title":"International Journal of Molecular Sciences 2020"},{"key":"2016_CR68","doi-asserted-by":"publisher","first-page":"658862","DOI":"10.3389\/FGENE.2021.658862\/BIBTEX","volume":"12","author":"HY Jo","year":"2022","unstructured":"Jo, H. Y., Seo, H. H., Gil, D., et al. (2022). Single-Cell RNA sequencing of human pluripotent stem cell-Derived macrophages for quality control of the cell therapy product. Frontiers in Genetics, 12, 658862. https:\/\/doi.org\/10.3389\/FGENE.2021.658862\/BIBTEX","journal-title":"Frontiers in Genetics"},{"issue":"1 15","key":"2016_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13287-024-03785-2","volume":"15","author":"M Ackermann","year":"2024","unstructured":"Ackermann, M., Saleh, F., Abdin, S. M., et al. (2024). Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions. Stem Cell Research & Therapy 2024, 15(1 15), 1\u201321. https:\/\/doi.org\/10.1186\/S13287-024-03785-2","journal-title":"Stem Cell Research & Therapy 2024"},{"key":"2016_CR70","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1136\/JITC-2023-007705","volume":"11","author":"SM Abdin","year":"2023","unstructured":"Abdin, S. M., Paasch, D., Kloos, A., et al. (2023). Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia. Journal for Immunotherapy of Cancer, 11, 7705. https:\/\/doi.org\/10.1136\/JITC-2023-007705","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"2016_CR71","doi-asserted-by":"publisher","unstructured":"Lu, J., Ma, Y., Li, Q. (2024). CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomarker Research 2024 12:1 12:1\u201319. https:\/\/doi.org\/10.1186\/S40364-024-00637-2","DOI":"10.1186\/S40364-024-00637-2"},{"key":"2016_CR72","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/BLOOD-2021-148687","volume":"138","author":"S Pouyanfard","year":"2021","unstructured":"Pouyanfard, S., Fierro, M., & Kaufman, D. S. (2021). Development of chimeric antigen Receptor-Expressing iPSC-Derived macrophages with improved Anti-Tumor activity. Blood, 138, 1693\u20131693. https:\/\/doi.org\/10.1182\/BLOOD-2021-148687","journal-title":"Blood"},{"issue":"4 15","key":"2016_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-06616-7","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang, S., Wang, Y., Jia, J., et al. (2024). Advances in engineered macrophages: A new frontier in cancer immunotherapy. Cell Death & Disease 2024, 15(4 15), 1\u201312. https:\/\/doi.org\/10.1038\/s41419-024-06616-7","journal-title":"Cell Death & Disease 2024"},{"key":"2016_CR74","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/S41590-023-01687-8;SUBJMETA","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A., Yu, H., Lu, S., et al. (2024). A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nature Immunology, 25, 102\u2013116. https:\/\/doi.org\/10.1038\/S41590-023-01687-8;SUBJMETA","journal-title":"Nature Immunology"},{"key":"2016_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-53659-7","volume":"15","author":"HY Huang","year":"2024","unstructured":"Huang, H. Y., Chen, Y. Z., Zhao, C., et al. (2024). Alternations in inflammatory macrophage niche drive phenotypic and functional plasticity of Kupffer cells. Nature Communications 2024, 15, 1. https:\/\/doi.org\/10.1038\/s41467-024-53659-7","journal-title":"Nature Communications 2024"},{"key":"2016_CR76","doi-asserted-by":"publisher","unstructured":"Liebold, I., Jawazneh, A., Al, Casar, C. (2024). Apoptotic cell identity induces distinct functional responses to IL-4 in efferocytic macrophages. Science (1979) 384:. https:\/\/doi.org\/10.1126\/SCIENCE.ABO7027;PAGEGROUP:STRING:PUBLICATION.","DOI":"10.1126\/SCIENCE.ABO7027"},{"key":"2016_CR77","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1538-7445.AM2023-3203","volume":"83","author":"M Esquerr\u00e9","year":"2023","unstructured":"Esquerr\u00e9, M., Holtzinger, A., Wagner, N., et al. (2023). Abstract 3203: EVOcells oncology: Tailored genetic engineering of iPSC-derived immune effector cells and combination with the right biologic therapeutics result in optimal killing of primary tumor cells from patients. Cancer Research, 83, 3203\u20133203. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-3203","journal-title":"Cancer Research"},{"key":"2016_CR78","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","volume":"16","author":"R Lovell-Badge","year":"2021","unstructured":"Lovell-Badge, R., Anthony, E., Barker, R. A., et al. (2021). ISSCR guidelines for stem cell research and clinical translation: The 2021 update. Stem Cell Reports, 16, 1398\u20131408. https:\/\/doi.org\/10.1016\/j.stemcr.2021.05.012","journal-title":"Stem Cell Reports"},{"key":"2016_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcyt.2022.08.001","volume":"25","author":"JL Dashnau","year":"2023","unstructured":"Dashnau, J. L., Xue, Q., Nelson, M., et al. (2023). A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell\u2013derived allogeneic cell therapies. Cytotherapy, 25, 1\u201313. https:\/\/doi.org\/10.1016\/j.jcyt.2022.08.001","journal-title":"Cytotherapy"},{"key":"2016_CR80","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","volume":"31","author":"J Shen","year":"2024","unstructured":"Shen, J., Lyu, S., Xu, Y., et al. (2024). Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell Stem Cell, 31, 1003\u20131019e9. https:\/\/doi.org\/10.1016\/j.stem.2024.04.012","journal-title":"Cell Stem Cell"},{"key":"2016_CR81","doi-asserted-by":"publisher","unstructured":"Zhou, Y., Li, M., Zhou, K. (2022). Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy. Cancers 2022, Vol 14, Page 2266 14:2266. https:\/\/doi.org\/10.3390\/CANCERS14092266","DOI":"10.3390\/CANCERS14092266"},{"key":"2016_CR82","doi-asserted-by":"publisher","first-page":"212481","DOI":"10.3390\/IJMS21072481","volume":"21","author":"A Lipus","year":"2020","unstructured":"Lipus, A., Janosz, E., Ackermann, M., et al. (2020). Targeted integration of inducible Caspase-9 in human iPSCs allows efficient in vitro clearance of iPSCs and iPSC-Macrophages. International Journal of Molecular Sciences 2020, 21, 212481. https:\/\/doi.org\/10.3390\/IJMS21072481","journal-title":"International Journal of Molecular Sciences 2020"},{"key":"2016_CR83","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.iotech.2023.100409","volume":"20","author":"G Jin","year":"2023","unstructured":"Jin, G., Chang, Y., & Bao, X. (2023). Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma. Immuno-Oncology and Technology, 20, 100409. https:\/\/doi.org\/10.1016\/j.iotech.2023.100409","journal-title":"Immuno-Oncology and Technology"},{"key":"2016_CR84","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1158\/1538-7445.AM2024-5244","volume":"84","author":"K Haake","year":"2024","unstructured":"Haake, K., Mirenda, M., Bernard, Q., et al. (2024). Abstract 5244: SIRP\u03b1 knockout iPSC-derived macrophages (iMACs) are resistant to CD47-dependent Inhibition of phagocytosis and efficiently kill tumor cells in pre-clinical models. Cancer Research, 84, 5244\u20135244. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-5244","journal-title":"Cancer Research"},{"key":"2016_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-56637-9","volume":"16","author":"B Taciak","year":"2025","unstructured":"Taciak, B., Bialasek, M., Kubiak, M., et al. (2025). Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism. Nature Communications 2025, 16, 1. https:\/\/doi.org\/10.1038\/s41467-025-56637-9","journal-title":"Nature Communications 2025"},{"issue":"1 41","key":"2016_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13046-022-02327-Z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan, K., Farrukh, H., Chittepu, V. C. S. R., et al. (2022). CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy. Journal of Experimental & Clinical Cancer Research 2022, 41(1 41), 1\u201321. https:\/\/doi.org\/10.1186\/S13046-022-02327-Z","journal-title":"Journal of Experimental & Clinical Cancer Research 2022"},{"key":"2016_CR87","doi-asserted-by":"publisher","unstructured":"Liu, J., Geng, X., Hou, J., & Wu, G. (2021). New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell International 2021 21:1 21:1\u20137. https:\/\/doi.org\/10.1186\/S12935-021-02089-2","DOI":"10.1186\/S12935-021-02089-2"},{"key":"2016_CR88","doi-asserted-by":"publisher","unstructured":"Blache, U., Popp, G., D\u00fcnkel, A. (2022). Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nature Communications 2022 13:1 13:1\u20135. https:\/\/doi.org\/10.1038\/s41467-022-32866-0","DOI":"10.1038\/s41467-022-32866-0"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02016-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:21:16Z","timestamp":1780482076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02016-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02016-0","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"31 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}